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fused patients; 6 out of 31, 19.4% in patients transfused withMulticenter trial of one HLA-DR–matched or mismatched
one DR-matched blood; and 13 out of 39, 33.3% in patientsblood transfusion prior to cadaveric renal transplantation.
transfused with mismatched blood.Background. The beneficial effect of blood transfusions be-
Conclusion. The results of our prospective randomized trialfore cadaveric renal transplantation on allograft survival, al-
showed that in a population of naive patients, one transfusionthough previously well documented, has become controversial
mismatched or matched for one HLA-DR antigen given priorin light of their adverse effects. Recently, it has been suggested
to renal transplantation had no significant effect on the inci-that their clinical benefits are due to HLA-DR sharing between
dence and severity of acute rejection, and did not influencethe blood donor and recipient.
overall long-term graft outcome. Considering the potentiallyMethods. In this prospective study, 144 naive patients were
deleterious adverse effects of blood transfusions, the costs, andrandomly assigned to receive one unit of blood matched for
the considerable logistical efforts required to select and typeone-HLA-DR antigen (N  49), or one unit of mismatched blood donors, such a procedure cannot be recommended in a
blood (N  48), or to remain untransfused (N  47). Graft routine practice for patients awaiting cadaveric kidney trans-
survival and acute rejection rate were analyzed in 106 cadaveric plantation.
renal allograft recipients receiving the same immunosuppres-
sive protocol.
Results. Graft survival was similar in the three groups at
The history of the transfusion of blood is an essentialone and five years: 91.7 and 80% in untransfused patients,
90.3 and 79.3% in patients transfused with one DR-antigen– part of the history and development of transplantation.
matched unit, and 92.3 and 83.7% in patients transfused with When the modern era of renal transplantation started
HLA-mismatched blood. The difference in the incidence of in the 1960s, the old concept of deleterious sensitization
six-month post-transplant acute rejections was not statistically of the patient to foreign proteins persisted, leading clini-
significant in the three groups: 12 out of 36, 33.3% in nontrans-
cians managing dialysis patients to the absolute avoid-
ance of blood products. This was the case until 1973,
when Opelz found that untransfused cadaveric renal
1 Current address: Establissment Franc¸ais des Greffres, Paris, France. transplant recipients had a poor graft outcome and pos-2 Contributing members (centers) of the Groupe Coope´ratif de Trans-
tulated the concept of a transfusion effect [1]. From thisplantation d’Ile de France include the following: F. Kriaa and B. Char-
pentier (Biceˆtre); J.M. Idatte, D. Charron, E. Thervet and C. Legendre time, a flurry of clinical, experimental, and fundamental
(Saint-Louis); P. Remy, C. Baron and B. Weil (Henri-Mondor); C. An- investigations confirmed the premise, and a stream oftoine and A. Duboust (Broussais); K. Akposso and J.D. Sraer (Tenon);
hypotheses successively attempted to explain the transfu-F. Mignon (Bichat); A. Pruna and M. Delahousse (Foch); and V.
Baudouin (Robert-Debre´). sion effect [2]. When cyclosporine (CsA) became the
cornerstone of immunosuppression, most clinical studiesKey words: kidney transplantation, graft survival, organ rejection, typ-
ing blood, transfusion policy, tolerogeneic effect. reported the progressive disappearance of the improve-
ment of renal allograft survival in transfused recipients
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diagnosis, immunosuppressive therapy, and overall pa- randomized to receive HLA-typed transfusions) who re-
ceived additional transfusions as medically indicatedtient care [4]. Second, it has become evident that the
detrimental effects of transfusions, that is, the risk of were withdrawn from further analysis regarding the in-
fluence of DR-matched transfusions on graft outcome.transmitting viral agents and the risk of sensitization,
outweighed a hypothetical and still poorly understood Patients who received a living-related donor graft or
patients who had received or were receiving anotherimmunologic effect. Finally, the availability of human
recombinant erythropoietin has eliminated the need for organ transplant other than a kidney, were also with-
drawn. Finally, patients who decided to leave the studyiterative transfusions in severely anemic dialysis patients.
These facts have led most centers in the United States, were withdrawn.
United Kingdom, and Scandinavia to reappraise their
Transfusion protocoltransfusion policy, while several European teams still
advocate blood transfusion protocols as a means of in- Blood units were obtained from the local blood banks.
The blood donors were selected from a panel of 300 bloodducing specific allograft tolerance [5]. In 1989, from ret-
rospective data Lagaaij et al suggested that the degree donors who had volunteered for anonymous blood dona-
tion and had subsequently been HLA A-B-DR typed.of HLA class II antigen compatibility between the blood
donor and the recipient might be crucial in the explana- The blood units were 220 to 350 mL leukocyte-rich packed
cell units containing approximately 108 to 109 leukocytestion of why a single transfusion led to immunization and
graft rejection in some cases, while in others, it improved per unit. A blood unit was transfused within 72 hours
of donation. Serum samples were collected weekly fromsurvival without an excessive risk of sensitization [6].
However, during the last decade, further controlled trials one to eight weeks after transfusion and then every three
months until renal transplantation. Lymphocytotoxicanalyzing the effect of matched transfusions have yielded
conflicting results [7–10]. Here we report the clinical re- anti-HLA antibodies were detected using a highly se-
lected panel of 40 lymphocytes containing all HLA classsults of the first prospective, multicenter randomized study
on the effects of a single leukocyte-rich blood transfu- I and class II. The National Institutes of Health (NIH)
lymphocytotoxicity technique was used with and withoutsion, either mismatched or matched for one HLA-DR
antigen, compared with zero transfusion, conducted in dithiothreitol to separate IgM antibodies from IgG. Fur-
thermore, blood samples from selected patients whoa population of naive untransfused dialysis patients
awaiting cadaveric renal transplantation. were transfused were collected before transfusion and
at 7, 28, and 60 days after transfusion for immunologic
studies as described elsewhere [11, 12]. Blood samples
METHODS
from the blood donors were collected three months after
Trial design the donation.
This open, randomized, prospective trial was con-
Tissue typingducted in eight kidney transplantation centers from the
Groupe Coope´ratif de Transplantation d’Ile de France Patients and blood donors were serologically typed
for HLA antigens A and B by standard complement-(GCIF) in France. Approval of the local ethics commit-
tee was obtained before the start of the study. After dependent cytotoxicity assays. HLA DRB1 alleles were
determined by genomic analysis: restriction fragmentgiving their written informed consent, male or female
patients undergoing dialysis and awaiting a first renal length polymorphism (RFLP) and/or polymerase chain
reaction (PCR) using HLA sequence-specific oligonucle-cadaver transplant were included. No age limit was re-
quired, and children were eligible for inclusion. Patients otides for DR loci (18 antigens at the generic level).
A transfusion was considered HLA-DR matched if awere randomly assigned either to receive one unit of
DR-matched blood or one unit of DR-mismatched blood minimum of one HLA-DRB1 allele was present in the
transfusion donor as well as recipient. Forty-eight pa-or to remain untransfused. Randomization was per-
formed immediately after patient inclusion in a 1:1:1 tients received a one DR-matched transfusion, and one
received a two DR-matched transfusion. A transfusionfashion using sealed envelopes, and was stratified by
the center. The information regarding DR compatibility was HLA-DR mismatched if no donor DRB1 allele was
shared with the recipient. Of note, the mean HLA class Ibetween blood donor and recipient remained blinded
for transfused patients and investigators. match per patient was similar in the two groups: 0.84 in
the DR matched group and 1.1 in the DR mismatchedPatients were excluded from the study if they had been
previously transfused, if female patients previously had group (difference P  NS).
been pregnant, and if preformed anti-HLA antibodies
Patients(IgG or IgM) were found in the serum. Patients partici-
pating in another clinical trial were also excluded. Pa- We recruited a total of 144 patients who were random-
ized from June 1992 to January 1996, and 106 patientstients from the three groups (including those who were
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Table 1. Summary of inclusions muromonab-CD3 monoclonal antibody, were given as
indicated in the case of refractory or rebound rejection1 HLA-DR- HLA-DR-
No matched mismatched if required. No other immunosuppressive drug was per-
transfusion transfusion transfusion Total mitted during the six-month post-transplant period.
Total included 47 49 48 144
Excluded 4 8 3 15 Study assessments and statistical analysis
Died on waiting list 1 2 2 5
Transplanted 36 31 39 106 The primary end points of the study were the number
Still awaiting a graft 6 8 4 18 and the severity of first biopsy-confirmed acute rejections
(Banff 93; borderline changes and grades I, II, and III)
and the graft survival rates. Differences in categorical
variables between the two groups were evaluated by chi-
received a kidney transplant before the end of 1998 square analysis. Continuous variables were compared
(Table 1). Forty-seven patients were allocated to remain between the groups by two-tailed unpaired t tests. Sur-
untransfused. Forty-nine were to receive a one HLA- vival rates and rejection cumulative incidence rates were
DR–matched transfusion, and 48 were to receive a one computed according to the Kaplan–Meier method and
HLA-DR–mismatched transfusion. Twenty-five patients are indicated as mean percentage  SEM. It was esti-
were withdrawn for the following reasons: five patients mated that a total of 87 transplant patients (29 in each
received additional transfusions (two in the nontrans- group) would be required to detect a 30% significant
fused group, and three in the group receiving HLA- difference in survival rates or rejection incidence with a
DR–compatible blood). Five patients died on the waiting power of at least 80%. The influence of factors on sur-
list. Three patients refused transfusions after randomiza- vival and rejection incidence was examined using the
tion to transfusion groups (two in the HLA-DR matched Cox proportional hazard model. Continuous variables
group and one in the HLA-DR mismatched group) for were categorized in groups with approximately similar
personal reasons. In one patient randomized in the trans- frequency except for age of donor (2 categories50 years,
fused group, no HLA-DR–compatible donor was found. 50 years) and cold ischemia time (30 hours,30 hours).
Two patients moved to another city and were withdrawn To identify independent prognostic factors, multivariate
for logistical reasons. One patient was withdrawn from stepwise regression analysis was performed using all of
the waiting list for medical reasons. Two patients re- the factors included in the previous analysis. The propor-
ceived a living donor graft and one a combined kidney- tionality assumption for each variable retained in the
liver transplantation. Five patients died of complications final model was verified before including them in the
during the dialysis period. Finally, 18 patients were still model. As the estimated hazard rate for graft survival
on the transplant waiting list at the end of the study. and for first episode of rejection over time was not con-
Patients who were transplanted had a minimum clinical stant between the three randomization groups, this co-
follow-up of one year (median follow-up of 55 months, variate was included in the model as a time-dependent
range of 17 to 83). covariate. Relative risks were presented as mean esti-
mates with a 95% confidence interval (95% CI). In the
Immunosuppressive therapy statistical procedures, the threshold level for statistical
All transplant recipients included in the GCIF study significance was fixed at P 0.05. The Statistical Package
received the same immunosuppressive protocol con- for Social Scientists (SPSS) was used for data manage-
sisting of CsA, prednisone, azathioprine, and prophylac- ment and analyses.
tic induction with antilymphocyte preparation. Induction
therapy consisted of 1.25 to 1.7 mg/kg antithymocyte
RESULTSglobulins (ATG Thymoglobulin; Imtix-Sangstat, Lyon,
Study populationFrance) given for 10 days. CsA was started on day 9, at
the initial daily dose of 6 to 8 mg/kg/day. Dosing was A total of 106 patients was included and received a
titrated to whole blood trough levels of 250 to 350 ng/mL transplant. Of these, 36 who were randomized in the
for the period of days 9 to 42 and 150 to 250 ng/mL nontransfusion group remained naive. Thirty-one were
thereafter. Azathioprine administered at 1 to 2 mg/kg/ transfused with one unit of DR-matched blood, and 39
day was started on day 1. A 2 mg/kg methylpredniso- received one unit of DR-mismatched blood. The baseline
lone bolus was given intravenously just before trans- characteristics of the three groups were similar with re-
plantation, and corticosteroids were tapered thereafter spect to age, sex, donor’s age, and the HLA matching
from 1 mg/kg at day 1 to 0.25 mg/kg at day 30 and to a between the organ donor and the recipient (Table 2). The
daily fixed baseline of 10 mg from day 60. First-line large majority of the study population was comprised of
antirejection therapy consisted of a daily 1 g intravenous male dialysis patients. Patients were slightly but signifi-
cantly (P  0.03) older in the group of patients whomethylprednisolone bolus over three days. ATGs, or
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Table 2. Clinical characteristics of the study patients
1 HLA-DR-matched HLA-DR-mismatched
No transfusion transfusion transfusion
Characteristics N36 N31 N39 P
Age years 3416 4312 3915 0.03
Sex N
Male 29 29 36 NS
Female 7 2 3
Lymphocytotoxic antibodies (IgG anti-T cells) None 1 patient (1/20) None NS
Donor creatinine lmol/L 8938 9630 11968 0.02
Donor age years 3716 4112 3915 NS
Cold ischemia time hour 258 2710 268 NS
Patients with delayed graft function N 10 (28%) 9 (29%) 10 (26%) NS
Mean HLA matching between kidney donor and recipient
HLA-A identities 0.60.6 10.7 1.10.5 0.03
HLA-B identities 0.70.7 0.60.6 0.70.6 NS
HLA-DR identities 1.20.7 10.7 1.10.5 NS
HLA-DR match between blood donor and kidney donor N
0 match 15 29
1 match 15 7 0.03
2 match 1 1
Mean (range) time transfusion-transplantation months 1815 (3–62) 2016 (2–55) NS
Post-transplant follow-up months 5023 4823 5424 NS
Plus–minus values are means  SD.
Table 3. Reasons for graft lossreceived a DR-matched transfusion. Results of anti-
lymphocytotoxic antibody detection after transfusion 1 HLA-DR- HLA-DR-
No matched mismatchedhave been previously published in detail [13]. No patient
transfusion transfusion transfusiondeveloped anti–B-cell panel-reactive antibodies. Only N36 N31 N39
one patient transfused with one DR-matched unit devel-
N % N % N %
oped significant IgG anti–T-cell antibodies (1 out of 20,
Death 2 5.6 3 9.7 1 2.65%), which were detected on day 35 and day 90 post-
Refractory acute rejection 2 5.6 1 3.2 — —
transfusion, respectively. The donor serum creatinine Chronic rejection 2 5.6 1 3.2 3 7.7
Primary non-function 1 2.8 — — — —before procurement was significantly (P 0.02) higher in
PTLD — — — — 1 2.6the DR-mismatched transfused group. HLA-A matching
Other — — 1 3.2 1 2.6
between kidney donor and recipient was significantly Total 7 19.4 6 19.3 6 15.4
(P  0.03) better in the DR-mismatched transfused PTLD is Post-transplant lymphoproliferative disease.
group compared with the nontransfused group. The inci-
dence of delayed graft function, defined by the require-
ment of one post-transplant dialysis session or more
DR-mismatched transfused group at one-year, respec-within the first week post-transplant, was similar in the
tively. At five years, patient survival rates were 92 three groups. The mean time from transfusion to trans-
5.4%, 86 6%, and 97 5%, respectively. The predomi-plantation was also similar for patients of the two transfu-
nant reasons for graft loss were chronic rejection, death,sion groups, and the mean post-transplant follow-up time
and refractory acute rejection (Table 3). The graft sur-was identical in the three groups.
vival rates after transplantation (Kaplan–Meier method)
Patient and graft survival were similar in the three groups at one-year (Fig. 1):
91.7 4.6%, 90.3 5.3%, and 92.3 4.3%, respectively.In total, six patients died during follow-up after trans-
At five years, the corresponding rates were 80  6.8%,plantation: two in the nontransfused group, three in the
79.3  7.6%, and 83.7  6.1%. In the Cox regressionone DR-matched transfused group, and one in the DR-
analysis, the factor of group randomization did not con-mismatched transfused group. The causes of death were
tribute significantly toward graft survival (P  0.41) andsepsis (N  2), pneumonia (N  1), liver failure (N 
the hazards ratio (HR) for nontransfused patients was1), adenocarcinoma (N 1), and neurological complica-
1.1 (95% CI, 0.51 to 2.48; P  0.76) and for patientstions of an inherited disease (N 1). The patient survival
transfused with DR-matched blood was 0.59 (95% CIrates (Kaplan–Meier method) for the study groups were
0.22 to 1.55; P  0.28). The occurrence of rejection wasnot statistically significantly different between the three
the only risk factor that contributed significantly (P groups: 100%, 100%, and 97  5% in the nontransfused
group, the one DR-matched transfused group, and the 0.05) to graft loss (HR for graft loss, 2.92; 1.01 to 8.43,
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Fig. 1. Five-year kidney graft survival in patients who received a single
pre-transplantation blood unit, with matching for one human lympho-
cyte antigen (HLA)-DR or without HLA-DR matching between recipi- Fig. 2. Kaplan–Meier estimates of the occurrence of first rejection
ents and blood donors, and in patients who received no transfusion. during the six-month post-transplant period for the three groups. Sym-
Symbols are: ( ) non-transfused patients (N  36); (– – –) one DR- bols are: ( ) non-transfused patients (N  36); (– – –) one DR-
matched unit transfused patients (N  31); ( • • • • ) DR-mismatched unit matched unit transfused patients (N  31); ( • • • • ) DR-mismatched unit
transfused patients (N  39). transfused patients (N  39).
95% CI). There was no significant contribution of the first rejection tended to be observed later in the group of
patients transfused with DR-mismatched blood (meanother risk factors: age of recipient; HLA-A, HLA-B, and
HLA-DR matching with the kidney donor; donor age; SEM): 32 days (50  12) versus 23 days (24  5) in the
sex and serum creatinine; and occurrence of delayed group of patients transfused with one DR-matched unit
graft function. and 17 days (mean SEM, 31 10) in the nontransfused
group, but this trend was not statistically significant.
Rejection incidence and severity Overall, the severity of rejection was comparable
We analyzed the incidence of biopsy-confirmed acute within the three groups (Table 4). A similar number of
rejection episodes during the six-month post-transplant patients had multiple episodes of rejection, and a similar
period. No patient received antirejection therapy with- number of patients required rescue therapy with muro-
out transplant biopsy being performed before or within monab-CD3 or antithymocyte globulin for the treatment
48 hours after antirejection therapy initiation. During this of rejection. Refractory rejection justified a switch from
period, acute rejection (defined as borderline changes CsA to tacrolimus (0.1 mg per kg and per day) in five
or a grade of 1 or higher according to the Banff 1993 patients, including three patients transfused with DR-
criteria) developed and required antirejection therapy mismatched blood, one patient transfused with DR-com-
in 12 of the 36 patients in the nontransfused group patible blood, and one nontransfused patient. Eight re-
(33.3%) as compared with 6 of the 31 in the one DR- jection episodes (44% of rejections) of grade 2 or grade
matched transfused group (19.4%), and 13 of the 39 3, in which vascular changes were present in transplant
in the DR-mismatched transfused group (33.3%). The biopsy, occurred in the group of patients transfused with
tendency to observe a lower frequency of rejection ob- DR-mismatched blood. This proportion was slightly but
served in the one DR-matched transfused group was not nonsignificantly lower in the group transfused with one
statistically significant (RR 0.59; 95% CI, 0.22 to 1.55; DR-matched blood and the nontransfused group: 30 and
P  0.28). The fraction of patients who remained free 25% of rejection episodes, respectively.
of rejection during the first six months was similar be-
tween the three groups (Fig. 2). In the multivariate Cox
DISCUSSIONregression analysis, neither DR matching with the kidney
The transfusion effect in kidney transplantation, estab-donor (RR for 0 DR match 1.5; 95% CI, 0.42 to 5.24;
lished by most clinical and experimental studies in theP  0.54) nor the age of recipient and the occurrence
1970 to 1980s, was later questioned in the light of the riskof post-transplant acute tubular necrosis contributed sig-
of transmitting infectious disease and of the detrimentalnificantly toward acute rejection. After six months, only
effect of sensitization, especially when protocols includedthree other patients had experienced late acute rejection:
several random transfusions. However, an amazing the-one patient in the one DR-matched transfused group at
ory reappraised the transfusion story when it was sug-day 341 and two in the DR-mismatched transfused group
at days 520 and 868, respectively. The median onset of gested by retrospective clinical data that HLA matching
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Table 4. Frequency and severity of rejection episodes during the six-month post-transplant period
1 DR-matched DR-mismatched
No transfusion transfusion transfusion
Variable N36 N31 N39
Number of patients with acute rejection 12 (33.3%) 6 (19.4%) 13 (33.3%)
Total number of acute rejection episodes 16 10 18
Frequency of rejections episodes/patient 0.44 0.32 0.46
Number of patients with recurrent or resistant rejections 4 (11.1%) 3 (9.7%) 5 (12.8%)
ALG/ATG/OTK3 use
Number of patients 4 (11.1%) 3 (9.7%) 3 (7.7%)
Histology
Number of Grade 1–Borderline rejections 12 (75%) 7 (70%) 10 (56%)
Number of Grade 2–Grade 3 rejections 4 (25%) 3 (30%) 8 (44%)
Abbreviations are: ALG, antilymphocyte globulin; ATG, antithymocyte globulin; OKT3, muromonab-CD3.
between the transfusion donor and the recipient might the use of different techniques: by adding exogenous inter-
leukin-2 to the culture medium in order to ensure T-cellhave been the crucial factor influencing the “tolerogen-
eic” effect of a single blood transfusion [14]. Indeed, expansion, we were more easily able to detect donor-
specific sensitization of CTL after transfusion, and thesharing one HLA haplotype or at least one HLA-DR
antigen was reported to improve graft survival or to rate, kinetics, and intensities of such sensitization were
not significantly different between recipients of a onereduce the incidence of post-transplant acute rejection
episodes significantly in kidney graft recipients [6]. Im- HLA-DR–matched transfusion and of a mismatched trans-
fusion [12]. Furthermore, we were unable to detect anyportantly, experimental data, in conjunction with clinical
studies, showed that transfusions might have different significant microchimerism, as only transient microchimer-
ism was observed at one and/or four weeks after transfusionin vitro immunomodulatory effects, according to the de-
gree of HLA antigen sharing between the transfusion in 4 out of 22 patients transfused with one DR-antigen–
matched blood and 4 out of 19 patients transfused withdonor and the recipient. Sharing of one haplotype, or at
least one DR and one B antigen, led to deletion and/or mismatched blood (unpublished personal data). Recent
data from Strober et al, in a cadaver renal transplantinactivation of donor-specific cytotoxic T-cell precursors
(CTLp) that are associated with a selective loss of T-cell patient given pretransplant total lymphoid irradiation
and withdrawn from immunosuppressive drugs morereceptor V gene expression [15]. In studies conducted
in transplant patients, low frequencies of donor-specific that 12 years ago, showed that tolerance was maintained
in the absence of detectable donor microchimerism andcytotoxic T-lymphocyte precursors correlated with favor-
able graft outcome, emphasizing the clinical relevance of a in the presence of a vigorous reactivity to donor stimula-
tor cells in the mixed leukocyte reaction, suggesting thatspecific decrease in T-cell responses against alloantigens.
Therefore, some authors postulated that a tolerance state neither chimerism nor clonal deletion or anergy is re-
quired [22]. Our clinical data confirm these experimentalcould be induced by low-grade mixed chimerism with
donor lymphocytes homing in privileged sites after blood results. In the present prospective, randomized trial, pa-
tient survival, kidney graft survival, and the incidence oftransfusion [16], and that the induction of such chimerism
might depend on the degree of HLA matching between acute biopsy-confirmed rejection did not differ signifi-
cantly between the three study groups defined accordingthe transfusion donor and the recipient. Other authors
have reported that microchimerism was detectable up to to the pre-transplant transfusion policy: one HLA-DR
match transfusion, one HLA-DR–mismatch transfusion,eight weeks after transfusion and tended to be of shorter
duration after mismatched transfusions [17]. In contrast, or no transfusion. In other words, in our study, the history
of transfusion was not a significant risk factor for graftpatients who received a mismatched transfusion main-
tained or increased donor-specific CTLp frequencies and outcome parameters. Lagaaij et al reported a significantly
better five-year graft survival in renal transplant patientsdeveloped high-avidity CD8-independent CTL clones,
which might be hazardous for the subsequent allograft who received a transfusion matched for one HLA-DR
antigen: 81 versus 57% in those who received blood not[18]. However, further in vitro studies, including ours,
were unable to confirm the results of van Twuyver et al matched and 45% in those who remained naive untrans-
fused [6]. Such results, however, refer to a historical pe-[11, 19–21]. Various explanations have been proposed
to explain these discrepancies, such as the low number riod when recipients were treated with azathioprine and
steroids, and did not benefit from the huge improvementof leukocytes transfused in some studies [21] or the mod-
ulatory effect of transfusion on interleukin-2–producing in transplantation results observed with newer immuno-
suppressants. At that time, figures of 90% one-year grafthelper T lymphocytes [20]. Another explanation may be
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survival and 20% post-transplant rejection incidence ment available before the approval of newer agents such
as tacrolimus, mycophenolate mofetil, sirolimus, andwere commonly recorded. Indeed, further retrospective
studies and prospective trials on HLA-matched transfu- anti-CD25 monoclonal antibodies. We cannot exclude,
however, that transfusions might have different immuno-sion were unable to find any influence of transfusion his-
tory on kidney graft survival. van Hoof and van den Berg- logic modulatory effects according to the HLA compati-
bility between donor and recipient. These effects areLoonen failed to confirm the influence of DR matching
between the blood donor and the recipient in 147 naive only observed in vitro after transfusion and are weak
and transient, and their possible influence on the graftdialysis patients, including 38 who were transplanted
with CsA-based immunosuppression [9]. Middleton et al outcome remains questionable. Considering the costs
and the considerable logistical efforts required to selectcompared sensitization and graft outcome of transplant
patients who had been given one-HLA-DR antigen- and type blood donors and despite the low risk of delete-
rious sensitization (5% in the present study), a routinematched blood transfusion before transplantation with
control patients who received blood from random donors policy of HLA-compatible transfusion appears both pro-
hibitive and expensive and, therefore, is impractical in[23]. No difference in sensitization or in graft survival
was found. The incidence of rejection episodes was sig- most transplant centers.
In large transplant registries, such as the UNOS andnificantly reduced, but for comparison the investigators
used a historical control group who had received random Collaborative Transplant Study databases, graft survival
in nontransfused patients was reported in 1987 to 1988transfusions for which the match grade of the donors
was unknown. The most recent study on this topic, pub- to become the same as for transfused recipients. Accord-
ingly, the transfusion policy has changed to liberal uselished by Christiaans et al, was also retrospective and
used leukocyte-poor erythrocytes [10]. They did not find or strict avoidance in a majority of worldwide kidney
transplant centers, but some individual centers continuea significant difference in antibody formation after trans-
fusion, in rejection rate, or in graft survival after trans- to routinely apply a deliberate transfusion policy. In chil-
dren, known to mount severe immunologic reactions afterplantation between patients receiving DR-matched and
DR-mismatched blood. kidney transplantation, a retrospective study was recently
published showing that in patients who received two trans-Bayle et al used a different approach by analyzing the
effect of a single haplo- or semi-identical blood transfu- fusions under CsA coverage, no sensitization occurred,
and graft survival rates were significantly improved [25].sion in 52 kidney transplant recipients compared with a
historical group of 53 transplant patients in which three However, the authors had mixed recipients of cadaver
donor grafts who received random transfusions with re-random transfusions were given [8]. They found a very
significant beneficial effect of haploidentical transfusions cipients of living donor grafts in which donor-specific
transfusions were given. On the other hand, survivalperformed in naive patients. Naive patients from this
group did not develop post-transfusion HLA antibodies, rates were compared with a historical group of patients
who were transplanted during the previous period.and they experienced significantly fewer episodes of
acute rejection (2.7% of 36 patients) compared with 48 Of importance, the results of the Prospective Interna-
tional Collaborative Study on pretransplant transfusionsnaive control patients (20.8%), but no statistical differ-
ence was found in the whole population whatever the coordinated by Opelz, conducted from 1987 to 1994,
have established that graft survival was significantlytype of transfusion used. Blood donors were blood- and
bone marrow-registered donors as well as the patients’ higher in 205 transplant patients who received three ran-
dom blood transfusions prior to transplant than in thefamily, but no separate analysis was done according to
donor type. Another similar study was unable to confirm 218 untransfused patients (at 1 year, 90 vs. 82%, P 
0.02; at 5 years, 79 vs. 70%, P 0.025) [26]. Immunosup-these preliminary results [24].
While limited by the small size of the sample, our study pression protocols included CsA/prednisone or triple-
drug regimen with CsA, prednisone, and azathioprine.was properly designed, including a homogeneous cohort
of selected naive patients—that is, untransfused, without The proportion of patients who remained free of rejec-
tion was similar in the transfusion (46%) and the transfu-previous pregnancy or previous transplant—and it was
the first to our knowledge that was randomized with an sion-free (45%) groups. Because repeat rejections were
more frequent in the untransfused group, the authorsuntransfused control group. Our trial was designed in
1992, and considering the data of Lagaaij et al, we specu- assumed that the severity of rejections was more pro-
nounced when transfusions were not given. However, inlated that the five-year survival would improve by 35%
and/or the graft rejection episode incidence be reduced this study, the baseline characteristics of the patients
were not given, and a bias in patient selection cannot beby 30% with DR-matched transfusions [6]. In all patients
who were transplanted, we used a quadruple immuno- excluded. Furthermore, the causes of graft failures are
not mentioned, and it cannot be excluded that technicalsuppressive combination with CsA, ATG, azathioprine,
and steroids, which was the most powerful drug treat- or surgical failures, not related to immunologic events,
Hiesse et al: DR-matched transfusion in renal transplantation348
3. Time to abandon pre-transplant blood transfusions? (editorial)might have been responsible for the lower graft survival
Lancet 1:567–568, 1988
in the group of untransfused patients. Finally, with the 4. Kerman RH, Van Buren CT, Lewis RM, Kahan BD: Successful
transplantation of 100 untransfused cyclosporine-treated primaryavailability of newer immunosuppressive agents, it has
recipients of cadaveric renal allografts. Transplantation 45:37–40,been demonstrated that excellent results can be achieved
1988
with a low (10 to 20%) incidence of rejection episodes. In- 5. Hiesse C, Lang P: Transfusion protocols prior to renal transplanta-
tion: Questionnaire on current attitudes at French centers. Trans-terestingly, during the same period as when the transfu-
plant Proc 27:2180–2181, 1995sion effect was disappearing, UCLA/UNOS data showed
6. Lagaaij EL, Hennemann PH, Ruigrok M, et al: Effect of one-
that there was a gradual reduction in the effect of immu- HLA-DR-antigen-matched and completely HLA-DR-mismatched
blood transfusions on survival of heart and kidney allografts. N Englnologic risk factors previously known to determine the
J Med 321:701–705, 1989survival of transplants, such as sensitization and HLA
7. Middleton D, Martin J, Douglas JF: Effect on sensitization of
matching, while other demographic factors such as the giving HLA-DR-matched blood to potential renal transplant recip-
ients. Transplant Proc 24:2535–2536, 1992age of donors and the age of recipients have remained
8. Bayle F, Masson D, Zaoui P, et al: Beneficial effect of one HLAalmost unchanged [27].
haplo- or semi-identical transfusion versus three untyped blood
In summary, in our opinion, the debate on the interest units on alloimmunization and acute rejection episodes in first
renal allograft recipients. Transplantation 59:719–723, 1995of routine blood transfusions in kidney transplantation
9. van Hoof JP, Van Den Berg-Loonen PM: The influence of DRis to a large extent obsolete at the dawn of the third
match of blood donor and recipient on the formation of T- and
millennium. Attention should focus on factors having an B-cell antibodies and on renal allograft outcome. Transplant Int
5(Suppl 1):S599–S600, 1992impact on the quality of transplant kidneys (warm and cold
10. Christiaans MHL, Van Hoof JP, Nieman F, Van Den Berg-ischemia times, damage occurring during procurement) Loonen EM: HLA-DR matched transfusions. Transplantation
and factors able to compromise the renal mass of the kid- 67:1029–1035, 1999
11. Baudouin V, Ansart-Pirenne H, Soulimani N, et al: Cytokineney: age and sex of the donor, as well as the proper use
mRNA and protein expression in a mixed leukocyte reaction be-of nephrotoxic anticalcineurine agents, which are becoming fore and after allogeneic transfusions. Transplantation 66:376–384,
the key factors influencing the long-term function of renal 1998
12. Baudouin V, De Vitry N, Hiesse C, et al: Cytotoxic changestransplants. The intrinsic risk of transfusion is definitely
after HLA-DR match and HLA-DR mismatch blood transfusions.minimal, and our study is not sufficiently powerful to Transplantation 63:1155–1160, 1997
exclude a small immunomodulatory effect; however, a 13. Busson M, Hiesse C, Buisson C, et al: Lymphocytotoxic antibody
responses to one prospective HLA-DR typed blood transfusionchance of deleterious anti-HLA immunization remains,
in naive patients awaiting renal transplantation. Transplant Procwhich may close the transplantation gateway to an indi- 29:1415–1416, 1997
vidual patient, particularly given the scarcity of organ 14. Sachs DH: Specific transplantation tolerance. N Engl J Med 325:
1240–1242, 1991supply for subjects with the uncommon ABO and/or
15. van Twuyver E, Mooijaart RJD, Ten Berge IJM, et al: Pretrans-HLA groups. It may be more cost-effective to avoid plant blood transfusions revisited. N Engl J Med 325:1210–1213,
transfusion, particularly in high-risk patients, rather than 1991
16. De Waal LP, Van Twuyver E: Blood transfusions and allograftto continue hazardous transplantation attempts in highly
survival: Is mixed chimerism the solution for tolerance inductionsensitized recipients, after removal of anti-HLA antibod- in clinical transplantation? Crit Rev Immunol 10:417–425, 1991
ies by plasmapheresis or immunoadsorption. 17. Vervoordeldonk SF, Doumaid K, Remmerswaal EB, et al: Long-
term detection of microchimaerism in peripheral blood after pre-
transplantation blood transfusion. Br J Haematol 102:1004–1009,
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